PhoreMost, a UK-based biopharmaceutical company developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, have collaborated to study oncology targets currently considered undruggable.
The agreement
The POLARISqb Tachyon quantum computing platform will be used to scan billions of molecules from a large chemical space, to find novel molecular drugs, based on the information obtained from PhoreMost’s SITESEEKER phenotypic screening platform. This partnership aims to discover and develop the next generation of oncology therapies.
Official comments
Dr Shahar Keinan, POLARISqb’s CEO, said: “Quantum Computing technology is coming of age, allowing us to revolutionise drug discovery timelines and budgets, while improving the overall profile of the designed drugs. The experience and speed of PhoreMost’s technology is a great match to POLARISqb and we are excited to work together.”
Dr Chris Torrance, CEO, PhoreMost, commented: “This partnership represents the ultimate ambition for any collaboration between biology and technology, where the full diversity of newly identified druggable disease targets generated by biological PROTEINi shape-libraries can now be married to the most logical and rapid method of finding small-molecule drugs to them. This best-in-class intersection of biotech and AI is going to be an exciting and transformative milestone for the entire pharmaceutical industry.”
